Literature DB >> 27044750

Inhibition of MMP-9-dependent Degradation of Gelatin, but Not Other MMP-9 Substrates, by the MMP-9 Hemopexin Domain Blades 1 and 4.

Estefanía Ugarte-Berzal1, Jennifer Vandooren2, Elvira Bailón3, Ghislain Opdenakker2, Angeles García-Pardo4.   

Abstract

Degradation and remodeling of the extracellular matrix by matrix metalloproteinases (MMPs) plays important roles in normal development, inflammation, and cancer. MMP-9 efficiently degrades the extracellular matrix component gelatin, and the hemopexin domain of MMP-9 (PEX9) inhibits this degradation. To study the molecular basis of this inhibition, we generated GST fusion proteins containing PEX9 or truncated forms corresponding to specific structural blades (B1-B4) of PEX9. GST-PEX9 inhibited MMP-9-driven gelatin proteolysis, measured by gelatin zymography, FITC-gelatin conversion, and DQ-gelatin degradation assays. However, GST-PEX9 did not prevent the degradation of other MMP-9 substrates, such as a fluorogenic peptide, αB crystalline, or nonmuscular actin. Therefore, PEX9 may inhibit gelatin degradation by shielding gelatin and specifically preventing its binding to MMP-9. Accordingly, GST-PEX9 also abolished the degradation of gelatin by MMP-2, confirming that PEX9 is not an MMP-9 antagonist. Moreover, GST-B4 and, to a lesser extent, GST-B1 also inhibited gelatin degradation by MMP-9, indicating that these regions are responsible for the inhibitory activity of PEX9. Accordingly, ELISAs demonstrated that GST-B4 and GST-B1 specifically bound to gelatin. Our results establish new functions of PEX9 attributed to blades B4 and B1 and should help in designing specific inhibitors of gelatin degradation.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  PEX9 blades 1 and 4; catalysis; enzyme antagonist; enzyme catalysis; gelatin degradation; hemopexin; inhibition mechanism; inhibitor; matrix metalloproteinase (MMP)

Mesh:

Substances:

Year:  2016        PMID: 27044750      PMCID: PMC4882443          DOI: 10.1074/jbc.M115.708438

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

Review 1.  Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.

Authors:  Jialiang Hu; Philippe E Van den Steen; Qing-Xiang A Sang; Ghislain Opdenakker
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

2.  A 17-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds α4β1 integrin and inhibits MMP-9-induced functions in chronic lymphocytic leukemia B cells.

Authors:  Estefanía Ugarte-Berzal; Elvira Bailón; Irene Amigo-Jiménez; Cidonia L Vituri; Mercedes Hernández del Cerro; María José Terol; Juan P Albar; Germán Rivas; José A García-Marco; Angeles García-Pardo
Journal:  J Biol Chem       Date:  2012-06-22       Impact factor: 5.157

3.  A novel CD44-binding peptide from the pro-matrix metalloproteinase-9 hemopexin domain impairs adhesion and migration of chronic lymphocytic leukemia (CLL) cells.

Authors:  Estefanía Ugarte-Berzal; Elvira Bailón; Irene Amigo-Jiménez; Juan Pablo Albar; José A García-Marco; Angeles García-Pardo
Journal:  J Biol Chem       Date:  2014-04-16       Impact factor: 5.157

Review 4.  Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics.

Authors:  Christopher M Overall; G Angus McQuibban; Ian Clark-Lewis
Journal:  Biol Chem       Date:  2002 Jul-Aug       Impact factor: 3.915

Review 5.  Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins.

Authors:  Helene Piccard; Philippe E Van den Steen; Ghislain Opdenakker
Journal:  J Leukoc Biol       Date:  2006-12-21       Impact factor: 4.962

6.  Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain.

Authors:  Javier Redondo-Muñoz; Estefanía Ugarte-Berzal; María José Terol; Philippe E Van den Steen; Mercedes Hernández del Cerro; Martin Roderfeld; Elke Roeb; Ghislain Opdenakker; José A García-Marco; Angeles García-Pardo
Journal:  Cancer Cell       Date:  2010-02-17       Impact factor: 31.743

7.  The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors.

Authors:  Philippe E Van den Steen; Ilse Van Aelst; Vibeke Hvidberg; Helene Piccard; Pierre Fiten; Christian Jacobsen; Soren K Moestrup; Simon Fry; Louise Royle; Mark R Wormald; Russell Wallis; Pauline M Rudd; Raymond A Dwek; Ghislain Opdenakker
Journal:  J Biol Chem       Date:  2006-05-03       Impact factor: 5.157

8.  MMP-9-hemopexin domain hampers adhesion and migration of colorectal cancer cells.

Authors:  M Burg-Roderfeld; M Roderfeld; S Wagner; C Henkel; J Grötzinger; E Roeb
Journal:  Int J Oncol       Date:  2007-04       Impact factor: 5.650

9.  Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors.

Authors:  Christopher M Overall; Eric M Tam; Reinhild Kappelhoff; Andrea Connor; Tom Ewart; Charlotte J Morrison; Xose Puente; Carlos López-Otín; Arun Seth
Journal:  Biol Chem       Date:  2004-06       Impact factor: 3.915

10.  Novel transcription-factor-like function of human matrix metalloproteinase 3 regulating the CTGF/CCN2 gene.

Authors:  Takanori Eguchi; Satoshi Kubota; Kazumi Kawata; Yoshiki Mukudai; Junji Uehara; Toshihiro Ohgawara; Soichiro Ibaragi; Akira Sasaki; Takuo Kuboki; Masaharu Takigawa
Journal:  Mol Cell Biol       Date:  2008-01-02       Impact factor: 4.272

View more
  9 in total

Review 1.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 2.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

3.  Decreased homodimerization and increased TIMP-1 complexation of uteroplacental and uterine arterial matrix metalloproteinase-9 during hypertension-in-pregnancy.

Authors:  Juanjuan Chen; Zongli Ren; Minglin Zhu; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2017-05-12       Impact factor: 5.858

4.  Human Adventitial Fibroblast Phenotype Depends on the Progression of Changes in Substrate Stiffness.

Authors:  Rebecca A Scott; Karyn G Robinson; Kristi L Kiick; Robert E Akins
Journal:  Adv Healthc Mater       Date:  2020-02-27       Impact factor: 9.933

5.  Matrix metalloproteinase-9 and p53 involved in chronic fluorosis induced blood-brain barrier damage and neurocyte changes.

Authors:  Shen Qing-Feng; Xia Ying-Peng; Xu Tian-Tong
Journal:  Arch Med Sci       Date:  2019-03-04       Impact factor: 3.318

6.  Proteoform Analysis of Matrix Metalloproteinase-9/Gelatinase B and Discovery of Its Citrullination in Rheumatoid Arthritis Synovial Fluids.

Authors:  Bernard Grillet; Karen Yu; Estefania Ugarte-Berzal; Rik Janssens; Rafaela Vaz Sousa Pereira; Lise Boon; Erik Martens; Nele Berghmans; Isabelle Ronsse; Ilse Van Aelst; Pierre Fiten; René Conings; Jennifer Vandooren; Patrick Verschueren; Jo Van Damme; Paul Proost; Ghislain Opdenakker
Journal:  Front Immunol       Date:  2021-11-29       Impact factor: 7.561

7.  Molecular Interactions Stabilizing the Promatrix Metalloprotease-9·Serglycin Heteromer.

Authors:  Rangita Dawadi; Nabin Malla; Beate Hegge; Imin Wushur; Eli Berg; Gunbjørg Svineng; Ingebrigt Sylte; Jan-Olof Winberg
Journal:  Int J Mol Sci       Date:  2020-06-12       Impact factor: 5.923

8.  Characterization of Matrix Metalloprotease-9 Gene from Nile tilapia (Oreochromis niloticus) and Its High-Level Expression Induced by the Streptococcus agalactiae Challenge.

Authors:  Fu-Rui Liang; Qin-Qing Wang; Yun-Lin Jiang; Bei-Ying Yue; Qian-Zhi Zhou; Jiang-Hai Wang
Journal:  Biomolecules       Date:  2020-01-03

9.  Multifunctional Gelatin-Nanoparticle-Modified Chip for Enhanced Capture and Non-Destructive Release of Circulating Tumor Cells.

Authors:  Linying Xu; Tiantian Ma; Kelin Zhang; Qilin Zhang; Mingxia Yu; Xingzhong Zhao
Journal:  Micromachines (Basel)       Date:  2022-02-28       Impact factor: 2.891

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.